Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23454305 | 0.92 | CYP1A2 (0.72) | CYP1A2SCN5ASCN1ASCN2AALOX5AP | |
| SCHEMBL21835712 | 0.91 | CYP1A2 (0.61) | CYP1A2SCN5ASCN1ASCN2APIM1 | |
| SCHEMBL21835717 | 0.90 | CYP1A2 (0.60) | CYP1A2SCN5ASCN1ASCN2APIM1 | |
| SCHEMBL21835742 | 0.88 | CYP1A2 (0.57) | CYP1A2SCN5ASCN1ASCN2APIM1 | |
| SCHEMBL26539146 | 0.84 | CYP1A2 (0.83) | CYP1A2SCN5ASCN1ASCN2AALOX5AP | |
| SCHEMBL26539106 | 0.84 | CYP1A2 (0.85) | CYP1A2SCN5ASCN1ASCN2APIM1 | |
| SCHEMBL26539151 | 0.82 | CYP1A2 (0.66) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL26539129 | 0.80 | CYP1A2 (0.87) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL26540171 | 0.78 | CYP1A2 (0.62) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL24155938 | 0.77 | CYP1A2 (0.76) | CYP1A2SCN5ASCN1ASCN2APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | CYP1A2 1403/4885SCN5A 3/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.